Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This trial is going to evaluate the efficacy and safety of two regimens of DX (docetaxel plus
capecitabine)and XELOX (oxaliplatin plus capecitabine)as adjuvant chemotherapy for stage
IIIb-IIIc gastric cancer patients after curative D2/D2+ operation, and to investigate the
optimal adjuvant regimen for such extremely high risk patients.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital